Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.

Rahmi RM, Uchida AH, Rezende PC, Lima EG, Garzillo CL, Favarato D, Strunz CM, Takiuti M, Girardi P, Hueb W, Kalil Filho R, Ramires JA.

Diabetes Care. 2013 Jun;36(6):1654-9. doi: 10.2337/dc12-1495. Epub 2012 Dec 18.

2.

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

Hueb W, Uchida AH, Gersh BJ, Betti RT, Lopes N, Moffa PJ, Ferreira BM, Ramires JA, Wajchenberg BL.

Coron Artery Dis. 2007 Feb;18(1):55-9.

PMID:
17172931
3.

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.

Diabetes Care. 2007 Feb;30(2):217-23. Erratum in: Diabetes Care. 2007 May;30(5):1330.

PMID:
17259484
4.

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.

Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M.

Diabetes Res Clin Pract. 2010 Sep;89(3):216-23. doi: 10.1016/j.diabres.2010.04.017.

PMID:
20537746
5.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Filozof C, Gautier JF.

Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. Erratum in: Diabet Med. 2013 May;30(5):632.

PMID:
20536495
6.

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.

Foley JE, Sreenan S.

Horm Metab Res. 2009 Dec;41(12):905-9. doi: 10.1055/s-0029-1234042. Epub 2009 Aug 24. Erratum in: Horm Metab Res. 2009 Dec;41(12):909.

PMID:
19705345
7.

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S.

Horm Metab Res. 2008 Dec;40(12):892-5. doi: 10.1055/s-0028-1082334. Epub 2008 Aug 22.

PMID:
18726829
8.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x. Epub 2008 Feb 18.

PMID:
18284434
9.

Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.

[No authors listed]

Prescrire Int. 2013 May;22(138):121. No abstract available.

PMID:
23819170
10.

[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].

[No authors listed]

J Pharm Belg. 2009 Jun;(2):64-6. Review. French. No abstract available.

PMID:
19739530
11.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
12.

The role of vildagliptin in the management of type 2 diabetes mellitus.

Kleppinger EL, Helms K.

Ann Pharmacother. 2007 May;41(5):824-32. Epub 2007 Apr 24. Review.

PMID:
17456545
13.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
14.

Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease.

Costa LM, Rezende PC, Garcia RM, Uchida AH, Seguro LF, Scudeler TL, Bocchi EA, Krieger JE, Hueb W, Ramires JA, Filho RK.

Medicine (Baltimore). 2015 Aug;94(33):e1161. doi: 10.1097/MD.0000000000001161.

15.

Update: vildagliptin for the treatment of Type 2 diabetes.

Garber AJ, Sharma MD.

Expert Opin Investig Drugs. 2008 Jan;17(1):105-13. Review.

PMID:
18095923
16.
17.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
18.

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

Schweizer A, Dejager S, Bosi E.

Diabetes Obes Metab. 2009 Aug;11(8):804-12. doi: 10.1111/j.1463-1326.2009.01051.x. Epub 2009 May 19.

PMID:
19476473
19.

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M.

Diabetes Obes Metab. 2009 Oct;11(10):978-86. doi: 10.1111/j.1463-1326.2009.01080.x. Epub 2009 Jul 13.

PMID:
19614942
20.

Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.

Halimi S, Raccah D, Schweizer A, Dejager S.

Curr Med Res Opin. 2010 Jul;26(7):1647-56. doi: 10.1185/03007995.2010.485881. Review.

PMID:
20441397

Supplemental Content

Support Center